| Assay ID | Title | Year | Journal | Article |
|---|
| AID1136071 | Potentiation of dl-DOPA-induced behavioral effects in ICR mouse assessed as marked piloerection, profuse salivation, marked increased irritability and reactivity, jumping, squeaking and aggressive fighting at 0.1 mg/kg, ip administered 1 hr prior to dl-DO | 1978 | Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
| Study of the structural requirements for dopa potentiation and oxotremorine antagonism by L-prolyl-L-leucylglycinamide. |
| AID62460 | In vitro ability to enhance the binding of [3H]ADTN to dopamine receptor obtained from bovine caudate membranes at a concentration of 10E-6 M | 1993 | Journal of medicinal chemistry, Jan-22, Volume: 36, Issue:2
| Synthesis and dopamine receptor modulating activity of lactam conformationally constrained analogues of Pro-Leu-Gly-NH2. |
| AID61473 | Percent of Dopamine receptor D2 in low affinity state for the compound in presence of Gpp(NH)p | 1999 | Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
| Design, synthesis, and dopamine receptor modulating activity of spiro bicyclic peptidomimetics of L-prolyl-L-leucyl-glycinamide. |
| AID61467 | Percent of Dopamine receptor D2 in high affinity state for the compound in absence of Gpp(NH)p | 1999 | Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
| Design, synthesis, and dopamine receptor modulating activity of spiro bicyclic peptidomimetics of L-prolyl-L-leucyl-glycinamide. |
| AID226423 | Ratio of the high affinity state over low affinity state of dopamine D2 receptor in the absence of Gpp(NH)p. (pretreatment with 100 nM of compound). | 1999 | Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
| Design, synthesis, and dopamine receptor modulating activity of spiro bicyclic peptidomimetics of L-prolyl-L-leucyl-glycinamide. |
| AID62470 | Inhibitory constant of compound in absence of Gpp(NH)p calculated for the high affinity components of the [3H]spiroperidol binding to Dopamine receptor D2 | 1997 | Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
| Design, synthesis, and dopamine receptor modulating activity of diketopiperazine peptidomimetics of L-prolyl-L-leucylglycinamide. |
| AID735546 | Analgesic activity in Wistar rats assessed as increase in mechanical nociceptive threshold at 1 mg/kg, ip measured after 15 mins by paw pressure test | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Synthesis of an MIF-1 analogue containing enantiopure (S)-α-trifluoromethyl-proline and biological evaluation on nociception. |
| AID774975 | Positive allosteric modulation of human dopamine D2S receptor expressed in CHO cell membranes assessed as stimulation of [3H]-NPA binding at 10'-8 to 10'-4 M after 60 mins by beta scintillation counting analysis | 2013 | European journal of medicinal chemistry, Nov, Volume: 69 | Synthesis and allosteric modulation of the dopamine receptor by peptide analogs of L-prolyl-L-leucyl-glycinamide (PLG) modified in the L-proline or L-proline and L-leucine scaffolds. |
| AID587330 | Agonist activity at human dopamine D2 receptor at 10 nM | 2011 | Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5
| Tripeptide motifs in biology: targets for peptidomimetic design. |
| AID226425 | Ratio of the high affinity state over low affinity state of dopamine D2 receptor in the presence of Gpp(NH)p. (pretreatment with 100 nM of compound). | 1999 | Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
| Design, synthesis, and dopamine receptor modulating activity of spiro bicyclic peptidomimetics of L-prolyl-L-leucyl-glycinamide. |
| AID231434 | RH/RL ratio of the compound | 1997 | Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
| Design, synthesis, and dopamine receptor modulating activity of diketopiperazine peptidomimetics of L-prolyl-L-leucylglycinamide. |
| AID735539 | Analgesic activity in Wistar rats assessed as increase in mechanical nociceptive threshold at 1 mg/kg, ip treated 20 mins after 1 mg/kg, ip NO donor, L-arginine challenge measured after 15 to 45 mins by paw pressure test | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Synthesis of an MIF-1 analogue containing enantiopure (S)-α-trifluoromethyl-proline and biological evaluation on nociception. |
| AID61463 | Inhibitor constant of compound for high affinity component of [3H]spiroperidol/N-propylnorapomorphine binding to Dopamine receptor D2 in presence of Gpp(NH)p (pretreatment with 100 nM of compound) | 1999 | Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
| Design, synthesis, and dopamine receptor modulating activity of spiro bicyclic peptidomimetics of L-prolyl-L-leucyl-glycinamide. |
| AID62620 | Ability to enhance the binding of [3H]-ADTN to Dopamine receptor D2 isolated from bovine caudate membranes at 1 uM concentration | 1990 | Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
| Synthesis and biological evaluation of analogues of Pro-Leu-Gly-NH2 modified at the leucyl residue. |
| AID62617 | Percentage of receptor in the low affinity form for the compound to Dopamine receptor D2 in presence of Gpp(NH)p | 1997 | Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
| Design, synthesis, and dopamine receptor modulating activity of diketopiperazine peptidomimetics of L-prolyl-L-leucylglycinamide. |
| AID62301 | Compound was tested for enhancement of the binding of [3H]ADTN to dopamine receptors at concentration of 100 nM | 1986 | Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
| Synthesis of Pro-Leu-Gly-NH2 analogues modified at the prolyl residue and evaluation of their effects on the receptor binding activity of the central dopamine receptor agonist, ADTN. |
| AID282084 | Activity at human dopamine D2 receptor in NIH/3T3 cells assessed as enhancement of NPA-stimulated beta-galactosidase activity at 50 nM after 5 days by R-SAT assay | 2004 | Journal of medicinal chemistry, Dec-16, Volume: 47, Issue:26
| Design, synthesis and evaluation of a PLG tripeptidomimetic based on a pyridine scaffold. |
| AID61472 | Percent of Dopamine receptor D2 in low affinity state for the compound in absence of Gpp(NH)p (pretreatment with 100 nM of compound). | 1999 | Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
| Design, synthesis, and dopamine receptor modulating activity of spiro bicyclic peptidomimetics of L-prolyl-L-leucyl-glycinamide. |
| AID257907 | Stimulation of [3H]NPA binding to dopamine D2 receptor from bovine striatal membranes in presence of photoaffinity-labeling agents | 2006 | Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1
| Design and synthesis of photoaffinity-labeling ligands of the L-prolyl-L-leucylglycinamide binding site involved in the allosteric modulation of the dopamine receptor. |
| AID62500 | Percentage of receptor in the high affinity form for the compound to Dopamine receptor D2 in presence of Gpp(NH)p (pre treated with 1 uM) | 1997 | Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
| Design, synthesis, and dopamine receptor modulating activity of diketopiperazine peptidomimetics of L-prolyl-L-leucylglycinamide. |
| AID62305 | Compound was tested for enhancement of the binding of [3H]ADTN to dopamine receptors at concentration of 1 nM | 1986 | Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
| Synthesis of Pro-Leu-Gly-NH2 analogues modified at the prolyl residue and evaluation of their effects on the receptor binding activity of the central dopamine receptor agonist, ADTN. |
| AID1136962 | Inhibition of oxotremorine-induced tremor in ip dosed NMRI mouse administered 1 hr prior to oxotremorine challenge | 1979 | Journal of medicinal chemistry, Aug, Volume: 22, Issue:8
| Tripeptide analogues of melanocyte-stimulating hormone release-inhibiting hormone (Pro-Leu-Gly-NH2) as inhibitors of oxotremorine-induced tremor. |
| AID735538 | Analgesic activity in Wistar rats assessed as increase in latency of response to pain at 1 mg/kg, ip treated 20 mins after 10 mg/kg, ip NOS inhibitor, L-NAME challenge measured after 15 to 45 mins by hot plate test | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Synthesis of an MIF-1 analogue containing enantiopure (S)-α-trifluoromethyl-proline and biological evaluation on nociception. |
| AID62304 | Enhancement of [3H]-ADTN to dopamine receptors at concentration of 1 nM | 1986 | Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
| Dopamine receptor modulation by Pro-Leu-Gly-NH2 analogues possessing cyclic amino acid residues at the C-terminal position. |
| AID735545 | Analgesic activity in Wistar rats assessed as increase in latency of response to pain at 1 mg/kg, ip measured after 15 mins by hot plate test | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Synthesis of an MIF-1 analogue containing enantiopure (S)-α-trifluoromethyl-proline and biological evaluation on nociception. |
| AID280941 | Cytotoxicity against mouse L1210/0 cells after 48 hrs | 2007 | Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
| Probing the anticancer activity of nucleoside analogues: a QSAR model approach using an internally consistent training set. |
| AID62294 | Tested for ability to enhance the binding of the dopamine receptor agonist [3H]ADTN to striatal dopamine receptors in vitro | 1993 | Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
| Dopamine receptor modulation by a highly rigid spiro bicyclic peptidomimetic of Pro-Leu-Gly-NH2. |
| AID735537 | Analgesic activity in Wistar rats assessed as increase in latency of response to pain at 1 mg/kg, ip treated 20 mins after 1 mg/kg, ip NO donor, L-arginine challenge measured after 15 to 45 mins by hot plate test | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Synthesis of an MIF-1 analogue containing enantiopure (S)-α-trifluoromethyl-proline and biological evaluation on nociception. |
| AID282085 | Activity at human dopamine D2 receptor in NIH/3T3 cells assessed as enhancement of NPA-stimulated beta-galactosidase activity at 100 nM after 5 days by R-SAT assay | 2004 | Journal of medicinal chemistry, Dec-16, Volume: 47, Issue:26
| Design, synthesis and evaluation of a PLG tripeptidomimetic based on a pyridine scaffold. |
| AID61471 | Percent of Dopamine receptor D2 in low affinity state for the compound in absence of Gpp(NH)p | 1999 | Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
| Design, synthesis, and dopamine receptor modulating activity of spiro bicyclic peptidomimetics of L-prolyl-L-leucyl-glycinamide. |
| AID257906 | Stimulation of [3H]NPA binding to dopamine D2 receptor in bovine striatal membranes | 2006 | Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1
| Design and synthesis of photoaffinity-labeling ligands of the L-prolyl-L-leucylglycinamide binding site involved in the allosteric modulation of the dopamine receptor. |
| AID62299 | Ability to enhance the binding of [3H]- ADTN to dopamine receptor from freshly dissected bovine caudate at 1 uM; Range is 25-40 | 1993 | Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
| Bicyclic thiazolidine lactam peptidomimetics of the dopamine receptor modulating peptide Pro-Leu-Gly-NH2. |
| AID62477 | Inhibitory constant of compound in presence of Gpp(NH)p calculated for the low affinity components of the [3H]spiroperidol binding to Dopamine receptor D2 | 1997 | Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
| Design, synthesis, and dopamine receptor modulating activity of diketopiperazine peptidomimetics of L-prolyl-L-leucylglycinamide. |
| AID62303 | Compound was tested for enhancement of the binding of [3H]-ADTN to dopamine receptors at concentration of 10 nM | 1986 | Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
| Synthesis of Pro-Leu-Gly-NH2 analogues modified at the prolyl residue and evaluation of their effects on the receptor binding activity of the central dopamine receptor agonist, ADTN. |
| AID61465 | Inhibitor constant of compound for low affinity component of [3H]spiroperidol/N-propylnorapomorphine binding to Dopamine receptor D2 in absence of Gpp(NH)p (pretreatment with 100 nM of compound) | 1999 | Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
| Design, synthesis, and dopamine receptor modulating activity of spiro bicyclic peptidomimetics of L-prolyl-L-leucyl-glycinamide. |
| AID1807005 | Positive allosteric modulation of human D2 receptor expressed in CHO cells assessed as inhibition of forskolin stimulated cAMP accumulation by measuring dopamine EC50 at 0.01 nM pretreated for 10 mins followed by forskolin stimulation for 5 mins and measu | 2021 | Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
| Discovery of New Potent Positive Allosteric Modulators of Dopamine D |
| AID62474 | Inhibitory constant of compound in presence of Gpp(NH)p (Pre treated with 1 uM) calculated for the high affinity components of the [3H]spiroperidol binding to Dopamine receptor D2 | 1997 | Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
| Design, synthesis, and dopamine receptor modulating activity of diketopiperazine peptidomimetics of L-prolyl-L-leucylglycinamide. |
| AID62021 | Compound was evaluated for its ability to enhance the binding of the dopamine receptor agonist [3H]pramipexole to Dopamine receptor D2 at a concentration of 10E-9 M | 1998 | Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20
| Beta-analogs of PLG (L-prolyl-L-leucyl-glycinamide): ex-chiral pool syntheses and dopamine D2 receptor modulating effects. |
| AID62497 | Percentage of receptor in the high affinity form for the compound to Dopamine receptor D2 in absence of Gpp(NH)p | 1997 | Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
| Design, synthesis, and dopamine receptor modulating activity of diketopiperazine peptidomimetics of L-prolyl-L-leucylglycinamide. |
| AID61466 | Inhibitor constant of compound for low affinity component of [3H]spiroperidol/N-propylnorapomorphine binding to Dopamine receptor D2 in presence of Gpp(NH)p | 1999 | Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
| Design, synthesis, and dopamine receptor modulating activity of spiro bicyclic peptidomimetics of L-prolyl-L-leucyl-glycinamide. |
| AID62300 | Enhancement of [3H]ADTN to dopamine receptors at concentration of 100 nM | 1986 | Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
| Dopamine receptor modulation by Pro-Leu-Gly-NH2 analogues possessing cyclic amino acid residues at the C-terminal position. |
| AID62471 | Inhibitory constant of compound in absence of Gpp(NH)p calculated for the low affinity components of the [3H]spiroperidol binding to Dopamine receptor D2 | 1997 | Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
| Design, synthesis, and dopamine receptor modulating activity of diketopiperazine peptidomimetics of L-prolyl-L-leucylglycinamide. |
| AID118946 | Ability to reverse electroconvulsive shock-induced amnesia in rodents following 0.1 mg/kg i.m. administration. | 1986 | Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
| Modified di- and tripeptides of the C-terminal portion of oxytocin and vasopressin as possible cognition activation agents. |
| AID735542 | Analgesic activity in Wistar rats assessed as increase in mechanical nociceptive threshold at 1 mg/kg, ip treated 20 mins after 1 mg/kg, ip noncompetitive opiate receptor antagonist, naloxone challenge measured after 15 to 30 mins by paw pressure test | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Synthesis of an MIF-1 analogue containing enantiopure (S)-α-trifluoromethyl-proline and biological evaluation on nociception. |
| AID735541 | Analgesic activity in Wistar rats assessed as increase in latency of response to pain at 1 mg/kg, ip treated 20 mins after 1 mg/kg, ip noncompetitive opiate receptor antagonist, naloxone challenge measured after 15 to 30 mins by hot plate test | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Synthesis of an MIF-1 analogue containing enantiopure (S)-α-trifluoromethyl-proline and biological evaluation on nociception. |
| AID1136080 | Suppression of oxotremorine-induced tremor in ICR mouse at 20 mg/kg, ip pretreated for 1 hr followed by oxotremorine-challenge | 1978 | Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
| Study of the structural requirements for dopa potentiation and oxotremorine antagonism by L-prolyl-L-leucylglycinamide. |
| AID61461 | Inhibitor constant of compound for high affinity component of [3H]spiroperidol/N-propylnorapomorphine binding to Dopamine receptor D2 in absence of Gpp(NH)p (pretreatment with 100 nM of compound) | 1999 | Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
| Design, synthesis, and dopamine receptor modulating activity of spiro bicyclic peptidomimetics of L-prolyl-L-leucyl-glycinamide. |
| AID1600455 | Agonist activity at human D2 receptor expressed in NIH/3T3 cells co-expressing beta-galactosidase assessed as increase in beta-galactosidase activity at 10 uM incubated for 5 days by spectrophotometry relative to control | 2019 | Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18
| Applications of amide isosteres in medicinal chemistry. |
| AID774974 | Positive allosteric modulation of human dopamine D2S receptor expressed in CHO cell membranes assessed as stimulation of [3H]-NPA binding at 10'-12 to 10'-9 M after 60 mins by beta scintillation counting analysis | 2013 | European journal of medicinal chemistry, Nov, Volume: 69 | Synthesis and allosteric modulation of the dopamine receptor by peptide analogs of L-prolyl-L-leucyl-glycinamide (PLG) modified in the L-proline or L-proline and L-leucine scaffolds. |
| AID184108 | Maximal increase in rotations at a dose of 1 mg/kg, ip in 6-hydroxydopamine-lesioned rat model of hemi-parkinsonism. | 1999 | Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16
| Synthesis and dopamine receptor modulating activity of unsubstituted and substituted triproline analogues of L-prolyl-L-leucyl-glycinamide (PLG). |
| AID62302 | Enhancement of [3H]ADTN to dopamine receptors at concentration of 10 nM | 1986 | Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
| Dopamine receptor modulation by Pro-Leu-Gly-NH2 analogues possessing cyclic amino acid residues at the C-terminal position. |
| AID62492 | Inhibitory constant of compound in presence of Gpp(NH)p (Pre treated with 1 uM) calculated for the low affinity components of the [3H]spiroperidol binding to Dopamine receptor D2 | 1997 | Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
| Design, synthesis, and dopamine receptor modulating activity of diketopiperazine peptidomimetics of L-prolyl-L-leucylglycinamide. |
| AID61462 | Inhibitor constant of compound for high affinity component of [3H]spiroperidol/N-propylnorapomorphine binding to Dopamine receptor D2 in presence of Gpp(NH)p | 1999 | Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
| Design, synthesis, and dopamine receptor modulating activity of spiro bicyclic peptidomimetics of L-prolyl-L-leucyl-glycinamide. |
| AID61469 | Percent of Dopamine receptor D2 in high affinity state for the compound in presence of Gpp(NH)p | 1999 | Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
| Design, synthesis, and dopamine receptor modulating activity of spiro bicyclic peptidomimetics of L-prolyl-L-leucyl-glycinamide. |
| AID62345 | Inhibitory constant of compound in absence of Gpp(NH)p (Pre treated with 1 uM) calculated for the high affinity components of the [3H]spiroperidol binding to Dopamine receptor D2 | 1997 | Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
| Design, synthesis, and dopamine receptor modulating activity of diketopiperazine peptidomimetics of L-prolyl-L-leucylglycinamide. |
| AID63986 | Inhibitor constant of compound for high affinity component of [3H]spiroperidol/N-propylnorapomorphine binding to Dopamine receptor D2 in absence of Gpp(NH)p | 1999 | Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
| Design, synthesis, and dopamine receptor modulating activity of spiro bicyclic peptidomimetics of L-prolyl-L-leucyl-glycinamide. |
| AID62476 | Inhibitory constant of compound in presence of Gpp(NH)p calculated for the high affinity components of the [3H]spiroperidol binding to Dopamine receptor D2 | 1997 | Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
| Design, synthesis, and dopamine receptor modulating activity of diketopiperazine peptidomimetics of L-prolyl-L-leucylglycinamide. |
| AID1136073 | Potentiation of dl-DOPA-induced behavioral effects in ICR mouse assessed as marked piloerection, profuse salivation, marked increased irritability and reactivity, jumping, squeaking and aggressive fighting at 10 mg/kg, ip administered 1 hr prior to dl-DOP | 1978 | Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
| Study of the structural requirements for dopa potentiation and oxotremorine antagonism by L-prolyl-L-leucylglycinamide. |
| AID62613 | Percentage of receptor in the low affinity form for the compound to Dopamine receptor D2 in absence of Gpp(NH)p | 1997 | Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
| Design, synthesis, and dopamine receptor modulating activity of diketopiperazine peptidomimetics of L-prolyl-L-leucylglycinamide. |
| AID62482 | Percentage of receptor in the high affinity form for the compound to Dopamine receptor D2 in absence of Gpp(NH)p (pre treated with 1 uM) | 1997 | Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
| Design, synthesis, and dopamine receptor modulating activity of diketopiperazine peptidomimetics of L-prolyl-L-leucylglycinamide. |
| AID191727 | Ability (% reversal in rats) to reverse electroconvulsive shock-induced amnesia in rodents at a dose of 0.10 (mg/kg) (following intramuscular dosing) | 1986 | Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
| Modified di- and tripeptides of the C-terminal portion of oxytocin and vasopressin as possible cognition activation agents. |
| AID226424 | Ratio of the high affinity state over low affinity state of dopamine D2 receptor in the presence of Gpp(NH)p. | 1999 | Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
| Design, synthesis, and dopamine receptor modulating activity of spiro bicyclic peptidomimetics of L-prolyl-L-leucyl-glycinamide. |
| AID226422 | Ratio of the high affinity state over low affinity state of dopamine D2 receptor in the absence of Gpp(NH)p. | 1999 | Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
| Design, synthesis, and dopamine receptor modulating activity of spiro bicyclic peptidomimetics of L-prolyl-L-leucyl-glycinamide. |
| AID61470 | Percent of Dopamine receptor D2 in high affinity state for the compound in presence of Gpp(NH)p (pretreatment with 100 nM of compound). | 1999 | Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
| Design, synthesis, and dopamine receptor modulating activity of spiro bicyclic peptidomimetics of L-prolyl-L-leucyl-glycinamide. |
| AID1807012 | Induction of morphological changes in human differentiated SH-SY5Y cells assessed as appearance of detached cells at 200 uM measured after 48 hrs by phase-contrast microscopic analysis | 2021 | Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
| Discovery of New Potent Positive Allosteric Modulators of Dopamine D |
| AID118943 | Ability to reverse electroconvulsive shock-induced amnesia in rodents following 1 ug/kg i.m. administration. | 1986 | Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
| Modified di- and tripeptides of the C-terminal portion of oxytocin and vasopressin as possible cognition activation agents. |
| AID1136078 | Suppression of oxotremorine-induced tremor in ICR mouse at 1 mg/kg, ip pretreated for 1 hr followed by oxotremorine-challenge | 1978 | Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
| Study of the structural requirements for dopa potentiation and oxotremorine antagonism by L-prolyl-L-leucylglycinamide. |
| AID191723 | Ability (% reversal in rats) to reverse electroconvulsive shock-induced amnesia in rodents at a dose of 0.010 (mg/kg) administered intramuscularly (im) | 1986 | Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
| Modified di- and tripeptides of the C-terminal portion of oxytocin and vasopressin as possible cognition activation agents. |
| AID61468 | Percent of Dopamine receptor D2 in high affinity state for the compound in absence of Gpp(NH)p (pretreatment with 100 nM of compound). | 1999 | Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
| Design, synthesis, and dopamine receptor modulating activity of spiro bicyclic peptidomimetics of L-prolyl-L-leucyl-glycinamide. |
| AID62607 | Inhibitory constant of compound in absence of Gpp(NH)p (Pre treated with 1 uM) calculated for the low affinity components of the [3H]spiroperidol binding to Dopamine receptor D2 | 1997 | Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
| Design, synthesis, and dopamine receptor modulating activity of diketopiperazine peptidomimetics of L-prolyl-L-leucylglycinamide. |
| AID62614 | Percentage of receptor in the low affinity form for the compound to Dopamine receptor D2 in absence of Gpp(NH)p (pre treated with 1 uM) | 1997 | Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
| Design, synthesis, and dopamine receptor modulating activity of diketopiperazine peptidomimetics of L-prolyl-L-leucylglycinamide. |
| AID1136079 | Suppression of oxotremorine-induced tremor in ICR mouse at 4 mg/kg, ip pretreated for 1 hr followed by oxotremorine-challenge | 1978 | Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
| Study of the structural requirements for dopa potentiation and oxotremorine antagonism by L-prolyl-L-leucylglycinamide. |
| AID118944 | Ability to reverse electroconvulsive shock-induced amnesia in rodents following 0.01 mg/kg i.m. administration. | 1986 | Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
| Modified di- and tripeptides of the C-terminal portion of oxytocin and vasopressin as possible cognition activation agents. |
| AID62498 | Percentage of receptor in the high affinity form for the compound to Dopamine receptor D2 in presence of Gpp(NH)p | 1997 | Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
| Design, synthesis, and dopamine receptor modulating activity of diketopiperazine peptidomimetics of L-prolyl-L-leucylglycinamide. |
| AID1136072 | Potentiation of dl-DOPA-induced behavioral effects in ICR mouse assessed as marked piloerection, profuse salivation, marked increased irritability and reactivity, jumping, squeaking and aggressive fighting at 1 mg/kg, ip administered 1 hr prior to dl-DOPA | 1978 | Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
| Study of the structural requirements for dopa potentiation and oxotremorine antagonism by L-prolyl-L-leucylglycinamide. |
| AID61474 | Percent of Dopamine receptor D2 in low affinity state for the compound in presence of Gpp(NH)p (pretreatment with 100 nM of compound). | 1999 | Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
| Design, synthesis, and dopamine receptor modulating activity of spiro bicyclic peptidomimetics of L-prolyl-L-leucyl-glycinamide. |
| AID191721 | Ability (% reversal in rats) to reverse electroconvulsive shock-induced amnesia in rodents at a dose of 0.0010 (mg/kg) (following i.m. administration) | 1986 | Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
| Modified di- and tripeptides of the C-terminal portion of oxytocin and vasopressin as possible cognition activation agents. |
| AID61464 | Inhibitor constant of compound for low affinity component of [3H]spiroperidol/N-propylnorapomorphine binding to Dopamine receptor D2 in absence of Gpp(NH)p | 1999 | Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
| Design, synthesis, and dopamine receptor modulating activity of spiro bicyclic peptidomimetics of L-prolyl-L-leucyl-glycinamide. |
| AID1807006 | Positive allosteric modulation of human D2 receptor expressed in CHO cells assessed as inhibition of forskolin stimulated cAMP accumulation by measuring dopamine Emax at 0.01 nM pretreated for 10 mins followed by forskolin stimulation for 5 mins and measu | 2021 | Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
| Discovery of New Potent Positive Allosteric Modulators of Dopamine D |
| AID735540 | Analgesic activity in Wistar rats assessed as increase in mechanical nociceptive threshold at 1 mg/kg, ip treated 20 mins after 10 mg/kg, ip NOS inhibitor, L-NAME challenge measured after 15 to 45 mins by paw pressure test | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Synthesis of an MIF-1 analogue containing enantiopure (S)-α-trifluoromethyl-proline and biological evaluation on nociception. |
| AID282083 | Activity at human dopamine D2 receptor in NIH/3T3 cells assessed as enhancement of NPA-stimulated beta-galactosidase activity at 10 nM after 5 days by R-SAT assay | 2004 | Journal of medicinal chemistry, Dec-16, Volume: 47, Issue:26
| Design, synthesis and evaluation of a PLG tripeptidomimetic based on a pyridine scaffold. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |